XML 39 R25.htm IDEA: XBRL DOCUMENT
v3.20.1

Earnings Per Share | 12 Months Ended
--- | ---
Dec. 31, 2019
Earnings Per Share [Abstract] |
Earnings Per Share | Earnings Per Share Basic net income per share is calculated using the weighted average number of shares of the Company’s common stock issued and outstanding during a certain period, and is calculated by dividing net income by the weighted average number of shares of the Company’s common stock issued and outstanding during such period. Diluted net income per share is calculated using the weighted average number of common and potentially dilutive common shares outstanding during the period, using the as-if converted method for preferred stock and the treasury stock method for options and common stock warrants. Pursuant to the Merger Agreement, ApolloMed held back 10% of the shares of its common stock that were issuable to NMM shareholders (“Holdback Shares”) to secure indemnification of ApolloMed and its affiliates under the Merger Agreement. The Holdback Shares will be held for a period of up to 24 months, with 50% issued on the first anniversary of the merger and the remaining 50% issued on the second anniversary, after the closing of the Merger (to be distributed on a pro-rata basis to former NMM shareholders), during which ApolloMed may seek indemnification for any breach of, or noncompliance with, any provision of the Merger Agreement, by NMM. The Holdback Shares are excluded from the computation of basic earnings per share, but included in diluted earnings per share. As of December 31, 2019, APC held 17,290,317 shares of ApolloMed's common stock and as of December 31, 2018 and 2017, APC held 1,682,110 shares of ApolloMed’s common stock, which are treated as treasury shares for accounting purposes and not included in the number of shares of common stock outstanding used to calculate earnings per share (see Note 12). The noncontrolling interests in APC are allocated their share of ApolloMed’s income from APC’s ownership of ApolloMed common stock and this is included in the net income attributable to noncontrolling interests on the consolidated statements of income. Therefore, none of the shares of ApolloMed held by APC are considered outstanding for the purposes of basic or diluted earnings per share computation. Below is a summary of the earnings per share computations:
|  | Years ended December 31,
|  | 2019 |  | 2018 |  | 2017
Earnings per share – basic |  | $ | 0.41 |  |  | $ | 0.33 |  |  | $ | 1.01 |
Earnings per share – diluted |  | $ | 0.39 |  |  | $ | 0.29 |  |  | $ | 0.90 |
Weighted average shares of common stock outstanding – basic |  | 34,708,429 |  |  | 32,893,940 |  |  | 25,525,786 |
Weighted average shares of common stock outstanding – diluted |  | 36,403,279 |  |  | 37,914,886 |  |  | 28,661,735 |
Below is a summary of the shares included in the diluted earnings per share computations:
|  | Years ended December 31,
|  | 2019 |  | 2018 |  | 2017
Weighted average shares of common stock outstanding – basic |  | 34,708,429 |  |  | 32,893,940 |  |  | 25,525,786 |
10% shares held back pursuant to indemnification clause |  | — |  |  | 2,935,512 |  |  | 3,039,749 |
Stock options |  | 295,672 |  |  | 459,440 |  |  | 44,716 |
Warrants |  | 1,384,078 |  |  | 1,625,994 |  |  | 51,484 |
Restricted stock units |  | 15,100 |  |  | — |  |  | — |
Weighted average shares of common stock outstanding – diluted |  | 36,403,279 |  |  | 37,914,886 |  |  | 28,661,735 |

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -URI http://asc.fasb.org/topic&trid=2144383 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration